

WHAT IS CLAIMED IS:

1. A method of treating ulcerative colitis in a patient in need of such treatment,
comprising administering to said patient a therapeutically effective amount of
5 a pharmaceutical formulation comprising an antibody, wherein said antibody
binds to CD3.
2. The method according to Claim 1, wherein said ulcerative colitis is severe
steroid-refractory ulcerative colitis.
- 10 3. The method according to Claim 1, wherein said administering reduces the
severity of ulcerative colitis symptom of said patient.
4. The method according to Claim 3, wherein said treatment reduces the MTWSI
15 score or the MAYO score of said patient.
5. The method according to Claim 4, wherein said MTWSI score or said MAYO
score of said patient is reduced by at least 75%.
- 20 6. The method according to Claim 1, wherein said treatment causes remission of
ulcerative colitis.
7. The method according to Claim 6, wherein said remission lasts for at least 90
days
- 25 8. The method according to Claim 6, wherein said remission is achieved no more
than 30 days after said treatment.
9. The method according to Claim 1, wherein said antibody neutralizes CD3.
- 30 10. The method according to Claim 9, wherein said antibody has a binding affinity
for said human CD3 of at least 10^8 M^{-1} .

11. The method according to Claim 10, wherein said antibody has a binding affinity for said human CD3 of at least 10^9 M^{-1} .
12. The method according to Claim 1, wherein said antibody is a monoclonal antibody.
13. The method according to Claim 1, wherein said antibody is a chimeric antibody or a human antibody.
14. The method according to Claim 1, wherein said antibody is a humanized antibody.
15. The method according to Claim 14, wherein said humanized antibody is a humanized M291 antibody.
16. The method according to Claim 15, wherein said humanized M291 antibody is visilizumab.
17. The method according to Claim 1, wherein said antibody binds to the same epitope as visilizumab.
18. The method according to Claim 17, wherein said antibody has an amino acid sequence that is at least 80% identical to the amino acid sequence of visilizumab.
19. The method according to Claim 17, wherein said antibody has CDR regions that have amino acid sequences that are identical to the amino acid sequences of the CDR regions of visilizumab.
20. The method according to Claim 1, wherein the pharmaceutical formulation is administered parentally, intravenously, intramuscularly, or subcutaneously.
21. The method according to Claim 1, wherein said therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg.

22. The method according to Claim 21, wherein said therapeutically effective amount is from 0.005 mg/kg to 0.100 mg/kg.

5 23. The method according to Claim 20, wherein said therapeutically effective amount is 15 µg/kg or less.

24. The method according to Claim 23, wherein said therapeutically effective amount is 10 µg/kg or less.

10

25. The method according to Claim 1, wherein the patient is a human.

15

26. The method according to Claim 1, wherein said additional agents are one or more agents selected from the group consisting of methyprednisolone, hydrocortisone, ondansetron, acetaminophen, 6-mercaptopurine, and 5-aminosalicylic acid (5-ASA).